{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:33:23Z","timestamp":1790202803519,"version":"4.1.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Schizophrenia significantly impacts global health, with existing treatments primarily focusing on positive symptoms and often causing considerable side effects. KarXT (Xanomeline-Trospium), a novel treatment combining xanomeline, a muscarinic M1\/M4 receptor agonist, and trospium, targets a broader range of symptoms including negative and cognitive deficits, potentially with fewer side effects. This systematic review and meta-analysis evaluates the efficacy and safety of KarXT in treating schizophrenia, assessing symptom reduction and safety profiles compared to placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched PubMed, Embase, and Web of Science up to November 10, 2024, for randomized controlled trials (RCTs) assessing the efficacy and safety of KarXT in schizophrenia. Data were pooled using a random-effects model, assessing outcomes like Positive and Negative Syndrome Scale (PANSS) scores and incidence of treatment-emergent adverse events (TEAEs). R software (Version 4.4.) was used for meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Three RCTs involving 674 participants were included. KarXT significantly reduced total PANSS scores of mean difference (MD) \u20139.707 (95% CI: \u201312.329 to \u20137.085), with notable improvements in both negative (MD\u2009=\u2009\u20131.623; 95% CI: \u20132.461 to \u20130.785) and positive symptom subscales (MD\u2009=\u2009\u20133.213; 95% CI: \u20134.033 to \u20132.393). The treatment was associated with a higher incidence of TEAEs, predominantly constipation [risk ratio (RR): 2.77; 95% CI: 1.72\u20134.45] and nausea (RR: 4.87; 95% CI: 2.73\u20138.68) compared to placebo. Bayesian meta-analysis confirmed the results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>KarXT offers significant improvements in both negative and positive symptoms of schizophrenia with a manageable safety profile. Its potential as a transformative treatment for schizophrenia highlights the need for further research to confirm these findings and to fully understand its long-term efficacy and safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ijnp\/pyaf045","type":"journal-article","created":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T07:29:42Z","timestamp":1751786982000},"source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of the muscarinic receptor agonist KarXT (Xanomeline-Trospium) in schizophrenia: a systematic review, meta-analysis and Bayesian sensitivity analysis"],"prefix":"10.1093","volume":"29","author":[{"given":"Nikhil","family":"Sharma","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, National Institute of Pharmaceutical Education and Research , Guwahati 781101 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahalaqua N","family":"Khatib","sequence":"additional","affiliation":[{"name":"Division of Evidence Synthesis, Global Consortium of Public Health and Research, Datta Meghe Institute of Higher Education , Wardha ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roopashree","family":"R","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Biochemistry, School of Sciences, JAIN (Deemed to be University) , Bangalore, Karnataka ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandeep","family":"Kaur","sequence":"additional","affiliation":[{"name":"Department of Allied Healthcare and Sciences, Vivekananda Global University , Jaipur, Rajasthan 303012 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Srivastava","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, NIMS University , Jaipur ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Barwal","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Chandigarh Pharmacy College, Chandigarh Group of College, Jhanjeri , Mohali, Punjab 140307 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garbham Venkata Siva","family":"Prasad","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Raghu Engineering College , Visakhapatnam, Andhra Pradesh 531162 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranchal","family":"Rajput","sequence":"additional","affiliation":[{"name":"School of Applied and Life Sciences, Division of Research and Innovation, Uttaranchal University , Dehradun ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinamra","family":"Mittal","sequence":"additional","affiliation":[{"name":"Graphic Era Institute of Medical Sciences, Graphic Era (Deemed to be University) , Clement Town, Dehradun ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed","family":"Shabil","sequence":"additional","affiliation":[{"name":"University Center for Research and Development, Chandigarh University , Mohali, Punjab ,","place":["India"]},{"name":"Medical Laboratories Techniques Department, AL-Mustaqbal University , Hillah, Babil 51001 ,","place":["Iraq"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Kumar","sequence":"additional","affiliation":[{"name":"Centre of Research Impact and Outcome, Chitkara University , Rajpura, Punjab 140417 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0397-7904","authenticated-orcid":false,"given":"Ganesh","family":"Bushi","sequence":"additional","affiliation":[{"name":"Chitkara Centre for Research and Development, Chitkara University , Himachal Pradesh 174103 \u00a0","place":["India"]},{"name":"School of Pharmaceutical Sciences, Lovely Professional University , Phagwara ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachana","family":"Mehta","sequence":"additional","affiliation":[{"name":"Clinical Microbiology, RDC, Manav Rachna International Institute of Research and Studies , Faridabad, Haryana 121004 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakasini","family":"Satapathy","sequence":"additional","affiliation":[{"name":"Center for Global Health Research, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Saveetha University , Chennai ,","place":["India"]},{"name":"University of Cyberjaya , Persiaran Bestari, Cyber 11, Cyberjaya, Selangor Darul Ehsan 63000 ,","place":["Malaysia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5017-083X","authenticated-orcid":false,"given":"Sanjit","family":"Sah","sequence":"additional","affiliation":[{"name":"SR Sanjeevani Hospital , Kalyanpur, Siraha 56517 ,","place":["Nepal"]},{"name":"Department of Paediatrics, Dr. D. Y. Patil Medical College Hospital and Research Centre, Dr. D. Y. Patil Vidyapeeth (Deemed-to-be-University) , Pimpri, Pune, Maharashtra 411018 ,","place":["India"]},{"name":"Department of Public Health Dentistry, Dr. D.Y. Patil Dental College and Hospital, Dr. D.Y. Patil Vidyapeeth (Deemed-to-be-University) , Pune, Maharashtra 411018 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"key":"2026061819383069400_ref1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S2215-0366(21)00395-3","article-title":"Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990\u20132019: a systematic analysis for the global burden of disease study 2019","volume":"9","year":"2022","journal-title":"Lancet Psychiatr"},{"key":"2026061819383069400_ref2","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2147\/NDT.S225643","article-title":"Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment","volume":"16","author":"Correll","year":"2020","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2026061819383069400_ref3","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/sj.mp.4001556","article-title":"Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs","volume":"10","author":"Miyamoto","year":"2005","journal-title":"Mol Psychiatry"},{"key":"2026061819383069400_ref4","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/10673220600748486","article-title":"Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome","volume":"14","author":"Shirzadi","year":"2006","journal-title":"Harv Rev Psychiatry"},{"key":"2026061819383069400_ref5","first-page":"69","article-title":"Pharmacology of acetylcholine and cholinergic receptors","author":"Kokaz","year":"2020","journal-title":"Front Pharmacol"},{"key":"2026061819383069400_ref6","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2147\/NDT.S55104","article-title":"Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer\u2019s disease and schizophrenia","volume":"10","author":"Foster","year":"2014","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2026061819383069400_ref7","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1176\/appi.ajp.21101083","article-title":"Muscarinic acetylcholine receptor agonists as novel treatments for schizophrenia","volume":"179","author":"Paul","year":"2022","journal-title":"Am J Psychiatry"},{"key":"2026061819383069400_ref8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40261-024-01377-9","article-title":"Current findings and potential mechanisms of KarXT (Xanomeline\u2013Trospium) in schizophrenia treatment","volume":"44","author":"Azargoonjahromi","year":"2024","journal-title":"Clin Drug Investig"},{"key":"2026061819383069400_ref9","doi-asserted-by":"crossref","first-page":"1421554","DOI":"10.3389\/fpsyt.2024.1421554","article-title":"The potential of muscarinic M1 and M4 receptor activators for the treatment of cognitive impairment associated with schizophrenia","volume":"15","author":"Yohn","year":"2024","journal-title":"Front Psychiatry"},{"key":"2026061819383069400_ref10","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1517\/17425255.2012.714365","article-title":"Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females","volume":"8","author":"Leone Roberti Maggiore","year":"2012","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2026061819383069400_ref11","doi-asserted-by":"crossref","first-page":"102153","DOI":"10.1016\/j.cpcardiol.2023.102153","article-title":"Cardiovascular consequences of financial stress: a systematic review and meta-analysis","volume":"49","author":"Swarup","year":"2024","journal-title":"Curr Probl Cardiol"},{"key":"2026061819383069400_ref12","article-title":"What is GRADE?","volume":"2021","author":"Siemieniuk","year":"2021","journal-title":"BMJ Best Practice"},{"key":"2026061819383069400_ref13","doi-asserted-by":"crossref","first-page":"2398870","DOI":"10.1080\/21645515.2024.2398870","article-title":"Comment on: \"efficacy and safety of tebentafusp in patients with metastatic uveal melanoma: a systematic review and meta-analysis\"","volume":"20","author":"Shabil","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"2026061819383069400_ref14","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2017015","article-title":"Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia","volume":"384","author":"Brannan","year":"2021","journal-title":"N Engl J Med"},{"key":"2026061819383069400_ref15","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/S0140-6736(23)02190-6","article-title":"Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial","volume":"403","author":"Kaul","year":"2024","journal-title":"Lancet"},{"key":"2026061819383069400_ref16","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1001\/jamapsychiatry.2024.0785","article-title":"Efficacy and safety of Xanomeline-Trospium chloride in schizophrenia a randomized clinical trial","volume":"81","author":"Kaul","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"2026061819383069400_ref17","doi-asserted-by":"crossref","first-page":"11983","DOI":"10.4088\/JCP.11m07162","article-title":"Minimum clinically important difference in the positive and negative syndrome scale with data from the clinical antipsychotic trials of intervention effectiveness (CATIE)","volume":"73","author":"Hermes","year":"2012","journal-title":"J Clin Psychiatry"},{"key":"2026061819383069400_ref18","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1038\/sj.npp.1301325","article-title":"Defining \u2018response\u2019in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs","volume":"32","author":"Leucht","year":"2007","journal-title":"Neuropsychopharmacology."},{"key":"2026061819383069400_ref19","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jpsychires.2024.11.047","article-title":"Efficacy and safety of xanomeline-trospium chloride in schizophrenia: a systematic review and meta-analysis","volume":"181","author":"Menegaz de Almeida","year":"2025","journal-title":"J Psychiatr Res"},{"key":"2026061819383069400_ref20","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1176\/appi.ajp.20240076","article-title":"The impact of Xanomeline and Trospium chloride on cognitive impairment in acute schizophrenia: replication in pooled data from two phase 3 trials","volume":"182","author":"Horan","year":"2025","journal-title":"Am J Psychiatry"},{"key":"2026061819383069400_ref21","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2174\/1568007024606249","article-title":"Muscarinic receptors as a target for drugs treating schizophrenia","volume":"1","author":"Bymaster","year":"2002","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"2026061819383069400_ref22","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1016\/j.drudis.2019.08.009","article-title":"Cholinergic muscarinic M1 and M4 receptors as therapeutic targets for cognitive, behavioural, and psychological symptoms in psychiatric and neurological disorders","volume":"24","author":"Erskine","year":"2019","journal-title":"Drug Discov Today"},{"key":"2026061819383069400_ref23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10286-024-01016-5","article-title":"Muscarinic control of cardiovascular function in humans: a review of current clinical evidence","volume":"34","author":"Palma","year":"2024","journal-title":"Clin Auton Res"},{"key":"2026061819383069400_ref24","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1176\/appi.ajp.2008.06091591","article-title":"Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia","volume":"165","author":"Shekhar","year":"2008","journal-title":"Am J Psychiatry"},{"key":"2026061819383069400_ref25","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1016\/S0140-6736(22)01990-0","article-title":"Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial","volume":"400","author":"Krystal","year":"2022","journal-title":"Lancet"},{"key":"2026061819383069400_ref26","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1586\/ern.09.143","article-title":"Effect of second-generation antipsychotics on cognition: current issues and future challenges","volume":"10","author":"Hill","year":"2010","journal-title":"Expert Rev Neurother"},{"key":"2026061819383069400_ref27","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000033.pub3","article-title":"Industry sponsorship and research outcome","volume":"2017","author":"Lundh","year":"2017","journal-title":"CDSR."}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ijnp\/advance-article-pdf\/doi\/10.1093\/ijnp\/pyaf045\/63686950\/pyaf045.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/29\/6\/pyaf045\/63686950\/pyaf045.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/29\/6\/pyaf045\/63686950\/pyaf045.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T23:38:43Z","timestamp":1781825923000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article\/doi\/10.1093\/ijnp\/pyaf045\/8190028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyaf045","relation":{},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2025,7,7]]},"article-number":"pyaf045"}}